National Research Center for Hematology, Russia

Quick facts

Marketed products

• Mesenchymal stromal cells · Immunology, Regenerative Medicine
  Mesenchymal stromal cells (MSCs) are bone marrow-derived multipotent cells that exert immunomodulatory and tissue-regenerative effects through paracrine signaling and direct cell-cell interactions.
• standard dose ARA-C · Oncology
  ARA-C (cytarabine) is a cytidine analog that inhibits DNA synthesis by being incorporated into DNA and blocking chain elongation, leading to cell death.

Phase 3 pipeline

• R-DA-EPOCH-21 · Oncology
  R-DA-EPOCH-21 is a chemotherapy regimen that combines rituximab, doxorubicin, etoposide, vincristine, cyclophosphamide, and prednisone.
• R-DA-EPOCH-21 + auto-SCT · Oncology
  R-DA-EPOCH-21 is a chemotherapy regimen that combines rituximab with the EPOCH chemotherapy regimen, followed by an autologous stem cell transplant.
• R-mNHL-BFM-90 · Oncology
  R-mNHL-BFM-90 is a chemotherapy regimen used to treat certain types of non-Hodgkin lymphoma.
• R-mNHL-BFM-90 + auto-SCT · Oncology
  R-mNHL-BFM-90 is a rituximab-based chemotherapy regimen combined with autologous stem cell transplantation to treat non-Hodgkin lymphoma by targeting CD20+ B cells and providing high-dose chemotherapy with stem cell rescue.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• National Research Center for Hematology, Russia portfolio CI brief
• National Research Center for Hematology, Russia pipeline updates RSS

Frequently asked questions about National Research Center for Hematology, Russia

Related

• Mesenchymal stromal cells · Immunology, Regenerative Medicine
• standard dose ARA-C · Oncology
• Sector hub: All tracked pharma companies